MCID: ADN089
MIFTS: 49

Adenosquamous Lung Carcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Adenosquamous Lung Carcinoma

MalaCards integrated aliases for Adenosquamous Lung Carcinoma:

Name: Adenosquamous Lung Carcinoma 12 15 17

Classifications:



External Ids:

Disease Ontology 12 DOID:4829
NCIt 50 C9133
UMLS 70 C0279557

Summaries for Adenosquamous Lung Carcinoma

Disease Ontology : 12 An adenosquamous carcinoma located in lung that derives from lung tissue composed of at least 10% by volume each of squamous cell carcinoma (SqCC) and adenocarcinoma (AdC) cells.

MalaCards based summary : Adenosquamous Lung Carcinoma is related to adenosquamous carcinoma and bronchiolo-alveolar adenocarcinoma. An important gene associated with Adenosquamous Lung Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are GPCR Pathway and Activation of cAMP-Dependent PKA. The drugs Paclitaxel and Metformin have been mentioned in the context of this disorder. Affiliated tissues include lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Adenosquamous lung carcinoma (AdSqLC) is a biphasic malignant tumor arising from lung tissue that is... more...

Related Diseases for Adenosquamous Lung Carcinoma

Diseases related to Adenosquamous Lung Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 180)
# Related Disease Score Top Affiliating Genes
1 adenosquamous carcinoma 30.5 PIK3CA KRAS EGFR
2 bronchiolo-alveolar adenocarcinoma 29.5 KRAS HRAS EGFR
3 large cell carcinoma 29.2 KRAS HRAS EGFR DDR2
4 lung non-squamous non-small cell carcinoma 28.7 KRAS KIF5B HRAS EGFR ALK
5 adenocarcinoma 28.5 PIK3CA KRAS HRAS EGFR BIRC5 ALK
6 lung squamous cell carcinoma 28.4 PIK3CA KRAS HRAS EGFR DDR2 ALK
7 malignant peritoneal mesothelioma 10.2 EGFR BIRC5
8 vulva squamous cell carcinoma 10.2 PIK3CA EGFR
9 signet ring lung adenocarcinoma 10.2 EGFR ALK
10 peritoneal mesothelioma 10.2 EGFR ALK
11 adenocarcinoma in situ 10.1 KRAS EGFR
12 brain stem glioma 10.1 PIK3CA EGFR
13 parameningeal embryonal rhabdomyosarcoma 10.1 PIK3CA ALK
14 ovarian clear cell adenofibroma 10.1 PIK3CA KRAS
15 gallbladder adenocarcinoma 10.1 PIK3CA EGFR
16 lymphoepithelioma-like carcinoma 10.1 EGFR ALK
17 occipital lobe neoplasm 10.1 KIF5B ALK
18 pleomorphic carcinoma 10.1 EGFR ALK
19 endometrioid ovary carcinoma 10.1 PIK3CA KRAS
20 pulmonary large cell neuroendocrine carcinoma 10.0 KIF5B ALK
21 endometrial serous adenocarcinoma 10.0 PIK3CA KRAS
22 tonsil cancer 10.0 PIK3CA EGFR
23 neuroendocrine carcinoma 10.0
24 pulmonary blastoma 10.0 KRAS EGFR
25 adult malignant schwannoma 9.9 HRAS BIRC5
26 high grade glioma 9.9 PIK3CA EGFR BIRC5
27 prostate squamous cell carcinoma 9.9 PIK3CA HRAS
28 cervical squamous cell carcinoma 9.9 PIK3CA KRAS EGFR
29 large cell neuroendocrine carcinoma 9.9 KIF5B EGFR ALK
30 epithelial-myoepithelial carcinoma 9.9 PIK3CA HRAS
31 myoepithelial carcinoma 9.9 PIK3CA HRAS
32 lipomatosis 9.9 PIK3CA KRAS
33 papillary adenoma 9.9 KRAS HRAS
34 hepatic flexure cancer 9.9 KRAS HRAS
35 gallbladder cancer 9.9 PIK3CA KRAS EGFR
36 trachea carcinoma in situ 9.9 KRAS HRAS
37 signet ring basal cell carcinoma 9.9 KRAS HRAS
38 cobblestone retinal degeneration 9.9 KRAS HRAS
39 small cell carcinoma 9.9 KRAS EGFR ALK
40 immature teratoma of ovary 9.9 KRAS HRAS
41 pancreatic signet ring cell adenocarcinoma 9.9 KRAS HRAS
42 signet ring cell adenocarcinoma 9.9 KRAS HRAS
43 descending colon cancer 9.9 KRAS HRAS
44 ampulla of vater benign neoplasm 9.9 KRAS HRAS
45 spitzoid melanoma 9.9 HRAS ALK
46 transverse colon cancer 9.9 KRAS HRAS
47 periampullary adenoma 9.9 KRAS HRAS
48 bone giant cell sarcoma 9.9 KRAS HRAS
49 appendiceal neoplasm 9.9 KRAS HRAS
50 gallbladder benign neoplasm 9.9 KRAS HRAS

Graphical network of the top 20 diseases related to Adenosquamous Lung Carcinoma:



Diseases related to Adenosquamous Lung Carcinoma

Symptoms & Phenotypes for Adenosquamous Lung Carcinoma

GenomeRNAi Phenotypes related to Adenosquamous Lung Carcinoma according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.29 HRAS KRAS PIK3CA EGFR
2 Decreased viability GR00055-A-2 10.29 HRAS KRAS PIK3CA EGFR
3 Decreased viability GR00055-A-3 10.29 KRAS
4 Decreased viability GR00106-A-0 10.29 KRAS
5 Decreased viability GR00221-A-1 10.29 DDR2 HRAS KRAS PIK3CA ALK EGFR
6 Decreased viability GR00221-A-2 10.29 DDR2 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.29 HRAS
8 Decreased viability GR00221-A-4 10.29 DDR2 PIK3CA ALK EGFR
9 Decreased viability GR00249-S 10.29 ALK
10 Decreased viability GR00301-A 10.29 KRAS
11 Decreased viability GR00381-A-1 10.29 KRAS
12 Decreased viability GR00402-S-2 10.29 DDR2 PIK3CA
13 Decreased cell migration GR00055-A-1 9.5 ALK
14 Decreased cell migration GR00055-A-3 9.5 EGFR HRAS PIK3CA

MGI Mouse Phenotypes related to Adenosquamous Lung Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.03 ALK BIRC5 DDR2 EGFR HRAS KIF5B
2 homeostasis/metabolism MP:0005376 10.01 ALK BIRC5 DDR2 EGFR HRAS KIF5B
3 mortality/aging MP:0010768 9.92 ALK BIRC5 DDR2 EGFR HRAS KIF5B
4 integument MP:0010771 9.85 ALK DDR2 EGFR HRAS KRAS PIK3CA
5 muscle MP:0005369 9.65 DDR2 EGFR HRAS KRAS PIK3CA
6 neoplasm MP:0002006 9.63 ALK DDR2 EGFR HRAS KRAS PIK3CA
7 no phenotypic analysis MP:0003012 9.35 DDR2 EGFR HRAS KRAS PIK3CA
8 skeleton MP:0005390 9.1 ALK DDR2 EGFR HRAS KRAS PIK3CA

Drugs & Therapeutics for Adenosquamous Lung Carcinoma

Drugs for Adenosquamous Lung Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 9)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
2
Metformin Approved Phase 2 657-24-9 4091 14219
3
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
4
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
5 Protein Kinase Inhibitors Phase 2
6 Tubulin Modulators Phase 2
7 Antimitotic Agents Phase 2
8 Albumin-Bound Paclitaxel Phase 2
9 Hypoglycemic Agents Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
2 Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC Active, not recruiting NCT02186847 Phase 2 Carboplatin;Metformin;Paclitaxel

Search NIH Clinical Center for Adenosquamous Lung Carcinoma

Genetic Tests for Adenosquamous Lung Carcinoma

Anatomical Context for Adenosquamous Lung Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Adenosquamous Lung Carcinoma:

19
Lung

MalaCards organs/tissues related to Adenosquamous Lung Carcinoma:

40
Lung

Publications for Adenosquamous Lung Carcinoma

Articles related to Adenosquamous Lung Carcinoma:

(show all 30)
# Title Authors PMID Year
1
Adenocarcinomatous-predominant subtype associated with a better prognosis in adenosquamous lung carcinoma. 61
32503451 2020
2
High Expression of Indoleamine 2, 3-Dioxygenase in Adenosquamous Lung Carcinoma Correlates with Favorable Patient Outcome. 61
30662547 2019
3
Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma. 61
29258673 2018
4
[Progression of diagnosis and treatment for adenosquamous lung carcinoma]. 61
28550661 2017
5
Predictive and prognostic value of preoperative serum tumor markers in resectable adenosqamous lung carcinoma. 61
27623437 2016
6
Pulmonary micropapillary-type adenosquamous carcinoma sharing epidermal growth factor receptor mutation in adenocarcinoma and squamous cell carcinoma. 61
28127432 2016
7
Genetic polymorphism rs3760396 of the chemokine (C-C motif) ligand 2 gene (CCL2) associated with the susceptibility of lung cancer in a pathological subtype-specific manner in Han-ancestry Chinese: a case control study. 61
27145753 2016
8
Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods. 61
26923333 2016
9
Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. 61
26486077 2015
10
Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma. 61
26072072 2015
11
Surgical specimen histology revealed inadequacy of conventional transbronchial needle aspiration sample in the diagnosis of adenosquamous lung carcinoma. 61
25973234 2015
12
Intracardiac Metastasis From Non-Small Cell Lung Cancer. 61
26258073 2015
13
Duodeno-colic fistula as a rare presentation of lung cancer - surgical treatment of a stage IV oligometastatic lung disease. 61
26197095 2015
14
EGFR gene mutations in patients with adenosquamous lung carcinoma. 61
24575772 2014
15
Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. 61
24481316 2014
16
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma. 61
24838432 2014
17
Case report: HIV negative isolated scrotal Kaposi's sarcoma. 61
25460481 2014
18
Synchronous left atrial myxoma and adenosquamous lung carcinoma. 61
23924482 2013
19
Metastasis of lung adenosquamous carcinoma to meningioma: case report with literature review. 61
24228131 2013
20
[Jejuno-jejunal intussusception as presentation of a primary lung carcinoma: a case report]. 61
22616498 2012
21
The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib. 61
23037472 2012
22
Erlotinib in non-small cell lung cancer's second line treatment. Clinical case. 61
25967692 2008
23
Prognosis and survival after radical resection of primary adenosquamous lung carcinoma. 61
15784375 2005
24
Adenosquamous lung carcinoma: clinical characteristics, surgical treament and prognosis. 61
12906147 2000
25
The adenosquamous lung carcinoma: clinical and pathological characteristics. 61
7698972 1994
26
Adenosquamous carcinoma of the lung: radiologic appearance. 61
8037019 1994
27
DNA ploidy pattern of each carcinomatous component in adenosquamous lung carcinoma. 61
8452418 1993
28
The increasing recognition of adenosquamous lung carcinoma (1977-1986). 61
1514535 1992
29
Clinical features of adenosquamous lung carcinoma in 127 patients. 61
2368969 1990
30
Adenosquamous lung carcinoma: clinical characteristics, treatment, and prognosis. 61
3675050 1987

Variations for Adenosquamous Lung Carcinoma

Cosmic variations for Adenosquamous Lung Carcinoma:

9 (show top 50) (show all 36919)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263727 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 9
2 COSM95442728 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 9
3 COSM85262562 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 9
4 COSM85263435 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 9
5 COSM95441934 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.599+122C>T p.? 3:50342996-50342996 9
6 COSM143112283 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 9
7 COSM101592316 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 9
8 COSM101606460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 9
9 COSM101614868 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 9
10 COSM101585076 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 9
11 COSM101614672 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 9
12 COSM143112460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 9
13 COSM143103178 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 9
14 COSM101592471 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 9
15 COSM102032968 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7406A>C p.? 16:72958371-72958371 9
16 COSM102040512 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1439C>A p.S480* 16:72798501-72798501 9
17 COSM102043690 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8060C>T p.S2687L 16:72787474-72787474 9
18 COSM87286137 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 9
19 COSM102031099 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7886C>A p.A2629D 16:72787648-72787648 9
20 COSM149303773 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 9
21 COSM149318853 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 9
22 COSM149318882 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 9
23 COSM149268808 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 9
24 COSM102042371 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-6501G>T p.? 16:72957466-72957466 9
25 COSM102037223 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7773G>T p.? 16:72958738-72958738 9
26 COSM149260552 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 9
27 COSM87273791 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 9
28 COSM87274581 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 9
29 COSM87284855 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 9
30 COSM149303017 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 9
31 COSM102022101 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6240C>G p.F2080L 16:72793700-72793700 9
32 COSM102032971 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7046G>T p.? 16:72958011-72958011 9
33 COSM87287980 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 9
34 COSM149309579 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 9
35 COSM102028052 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2928G>C p.Q976H 16:72797012-72797012 9
36 COSM149263533 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 9
37 COSM149322707 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 9
38 COSM87279299 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 9
39 COSM149327483 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 9
40 COSM87274095 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 9
41 COSM102037726 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.689G>T p.C230F 16:72889748-72889748 9
42 COSM102022617 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.13G>T p.G5C 16:72950930-72950930 9
43 COSM149265687 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 9
44 COSM87281915 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 9
45 COSM149269636 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 9
46 COSM102047871 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3243C>G p.I1081M 16:72796697-72796697 9
47 COSM149263422 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 9
48 COSM102041859 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1021C>T p.P341S 16:72811678-72811678 9
49 COSM87272331 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 9
50 COSM149290601 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 9

Expression for Adenosquamous Lung Carcinoma

Search GEO for disease gene expression data for Adenosquamous Lung Carcinoma.

Pathways for Adenosquamous Lung Carcinoma

Pathways related to Adenosquamous Lung Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 123)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 KRAS HRAS EGFR DDR2 BIRC5 ALK
2
Show member pathways
13.44 KRAS HRAS EGFR DDR2 ALK
3
Show member pathways
13.4 PIK3CA KRAS HRAS EGFR DDR2 ALK
4
Show member pathways
13.35 PIK3CA KRAS KIF5B HRAS EGFR
5
Show member pathways
13.31 KRAS HRAS EGFR DDR2 ALK
6
Show member pathways
13.26 PIK3CA KRAS HRAS EGFR BIRC5
7
Show member pathways
13.22 KRAS HRAS EGFR DDR2 ALK
8
Show member pathways
13.18 KRAS HRAS EGFR DDR2 ALK
9
Show member pathways
13.09 PIK3CA KRAS HRAS EGFR BIRC5
10
Show member pathways
12.97 PIK3CA KRAS HRAS EGFR BIRC5
11
Show member pathways
12.93 KRAS HRAS EGFR DDR2 ALK
12
Show member pathways
12.91 PIK3CA KRAS HRAS EGFR
13
Show member pathways
12.87 PIK3CA KRAS HRAS EGFR
14
Show member pathways
12.83 PIK3CA KRAS HRAS EGFR
15
Show member pathways
12.83 PIK3CA KRAS HRAS EGFR
16
Show member pathways
12.79 PIK3CA KRAS HRAS EGFR
17
Show member pathways
12.75 PIK3CA KRAS HRAS EGFR
18
Show member pathways
12.72 PIK3CA KRAS HRAS EGFR BIRC5
19
Show member pathways
12.71 PIK3CA KRAS HRAS BIRC5
20
Show member pathways
12.7 PIK3CA KRAS KIF5B HRAS
21
Show member pathways
12.69 PIK3CA KRAS HRAS EGFR
22
Show member pathways
12.66 PIK3CA KRAS HRAS EGFR
23
Show member pathways
12.65 PIK3CA KRAS HRAS EGFR
24
Show member pathways
12.63 PIK3CA KRAS HRAS BIRC5
25
Show member pathways
12.59 PIK3CA KRAS HRAS EGFR
26 12.56 PIK3CA KRAS HRAS EGFR
27
Show member pathways
12.55 PIK3CA KRAS HRAS EGFR
28
Show member pathways
12.54 PIK3CA KRAS HRAS EGFR
29
Show member pathways
12.45 PIK3CA KIF5B HRAS
30
Show member pathways
12.45 PIK3CA KRAS HRAS
31 12.45 PIK3CA KRAS HRAS EGFR
32
Show member pathways
12.43 KRAS HRAS EGFR
33
Show member pathways
12.42 PIK3CA KRAS HRAS
34
Show member pathways
12.41 PIK3CA KRAS HRAS EGFR
35
Show member pathways
12.4 PIK3CA KRAS HRAS EGFR
36
Show member pathways
12.39 PIK3CA KRAS HRAS
37
Show member pathways
12.39 PIK3CA KRAS HRAS DDR2
38 12.37 KIF5B HRAS EGFR
39
Show member pathways
12.37 PIK3CA KRAS HRAS EGFR ALK
40
Show member pathways
12.36 PIK3CA HRAS EGFR
41
Show member pathways
12.36 PIK3CA KRAS HRAS
42 12.36 PIK3CA KRAS HRAS EGFR BIRC5 ALK
43
Show member pathways
12.35 PIK3CA KRAS HRAS
44
Show member pathways
12.35 PIK3CA KRAS HRAS
45
Show member pathways
12.35 PIK3CA KRAS HRAS EGFR
46
Show member pathways
12.34 PIK3CA HRAS BIRC5
47
Show member pathways
12.33 PIK3CA KRAS HRAS EGFR
48
Show member pathways
12.33 PIK3CA KRAS HRAS EGFR BIRC5
49 12.3 PIK3CA KRAS HRAS
50
Show member pathways
12.3 PIK3CA KRAS HRAS EGFR

GO Terms for Adenosquamous Lung Carcinoma

Cellular components related to Adenosquamous Lung Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.26 PIK3CA KIF5B HRAS EGFR
2 receptor complex GO:0043235 8.8 EGFR DDR2 ALK

Biological processes related to Adenosquamous Lung Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.83 PIK3CA EGFR DDR2 ALK
2 cytokine-mediated signaling pathway GO:0019221 9.75 PIK3CA KRAS BIRC5
3 MAPK cascade GO:0000165 9.74 KRAS HRAS EGFR
4 positive regulation of protein phosphorylation GO:0001934 9.69 KRAS HRAS EGFR
5 protein autophosphorylation GO:0046777 9.67 EGFR DDR2 ALK
6 protein phosphorylation GO:0006468 9.65 PIK3CA EGFR DDR2 BIRC5 ALK
7 peptidyl-tyrosine phosphorylation GO:0018108 9.63 EGFR DDR2 ALK
8 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.61 EGFR DDR2 ALK
9 energy homeostasis GO:0097009 9.56 PIK3CA ALK
10 ERBB2 signaling pathway GO:0038128 9.55 PIK3CA EGFR
11 positive regulation of cell proliferation GO:0008284 9.55 KRAS HRAS EGFR DDR2 BIRC5
12 positive regulation of DNA replication GO:0045740 9.54 HRAS EGFR
13 positive regulation of kinase activity GO:0033674 9.54 EGFR DDR2 ALK
14 positive regulation of MAP kinase activity GO:0043406 9.5 KRAS HRAS EGFR
15 regulation of long-term neuronal synaptic plasticity GO:0048169 9.48 KRAS HRAS
16 response to isolation stress GO:0035900 9.4 KRAS HRAS
17 negative regulation of neuron apoptotic process GO:0043524 9.26 PIK3CA KRAS HRAS BIRC5
18 liver development GO:0001889 8.92 PIK3CA KRAS HRAS EGFR

Molecular functions related to Adenosquamous Lung Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.77 KRAS KIF5B EGFR BIRC5 ALK
2 ATP binding GO:0005524 9.65 PIK3CA KIF5B EGFR DDR2 ALK
3 kinase activity GO:0016301 9.62 PIK3CA EGFR DDR2 ALK
4 protein tyrosine kinase activity GO:0004713 9.33 EGFR DDR2 ALK
5 nucleotide binding GO:0000166 9.17 PIK3CA KRAS KIF5B HRAS EGFR DDR2
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR DDR2 ALK

Sources for Adenosquamous Lung Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....